vs
CARPENTER TECHNOLOGY CORP（CRS）とRevvity（RVTY）の財務データ比較。上の社名をクリックして会社を切り替えられます
CARPENTER TECHNOLOGY CORPの直近四半期売上が大きい（$811.5M vs $772.1M、Revvityの約1.1倍）。CARPENTER TECHNOLOGY CORPの純利益率が高く（17.2% vs 12.7%、差は4.5%）。CARPENTER TECHNOLOGY CORPの前年同期比売上増加率が高い（11.6% vs 5.9%）。Revvityの直近四半期フリーキャッシュフローが多い（$161.8M vs $124.8M）。過去8四半期でRevvityの売上複合成長率が高い（9.0% vs 0.8%）
カーペンター・テクノロジー・コーポレーションは、ステンレス鋼、耐食性ニッケル・銅・チタン合金、3D積層造形用粉末合金の開発・製造・流通を手掛ける。2018年度の売上構成は航空宇宙・防衛55%、産業・消費財17%、医療8%、運輸7%、エネルギー7%、流通6%となっている。
レブィティ（Revvity, Inc.）は米国のライフサイエンス・診断事業を手がける企業で、製薬およびバイオテクノロジー業界を主な顧客とし、特に新たな細胞治療や遺伝子治療の開発に関連するサービス・製品を提供している。前身は多岐にわたる事業を展開してきた老舗企業パーキンエルマーである。
CRS vs RVTY — 直接比較
損益計算書 — Q3 FY2026 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $811.5M | $772.1M |
| 純利益 | $139.6M | $98.4M |
| 粗利率 | 31.0% | — |
| 営業利益率 | 23.0% | 14.5% |
| 純利益率 | 17.2% | 12.7% |
| 売上前年比 | 11.6% | 5.9% |
| 純利益前年比 | 46.3% | 3.9% |
| EPS（希薄化後） | $2.77 | $0.86 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q1 26 | $811.5M | — | ||
| Q4 25 | $728.0M | $772.1M | ||
| Q3 25 | $733.7M | $698.9M | ||
| Q2 25 | $755.6M | $720.3M | ||
| Q1 25 | $727.0M | $664.8M | ||
| Q4 24 | $676.9M | $729.4M | ||
| Q3 24 | $717.6M | $684.0M | ||
| Q2 24 | $798.7M | $691.7M |
| Q1 26 | $139.6M | — | ||
| Q4 25 | $105.3M | $98.4M | ||
| Q3 25 | $122.5M | $46.7M | ||
| Q2 25 | $111.7M | $53.9M | ||
| Q1 25 | $95.4M | $42.2M | ||
| Q4 24 | $84.1M | $94.6M | ||
| Q3 24 | $84.8M | $94.4M | ||
| Q2 24 | $93.6M | $55.4M |
| Q1 26 | 31.0% | — | ||
| Q4 25 | 30.0% | — | ||
| Q3 25 | 29.5% | 53.6% | ||
| Q2 25 | 28.3% | 54.5% | ||
| Q1 25 | 27.6% | 56.5% | ||
| Q4 24 | 26.2% | — | ||
| Q3 24 | 24.6% | 56.3% | ||
| Q2 24 | 23.9% | 55.7% |
| Q1 26 | 23.0% | — | ||
| Q4 25 | 21.3% | 14.5% | ||
| Q3 25 | 20.9% | 11.7% | ||
| Q2 25 | 20.1% | 12.6% | ||
| Q1 25 | 19.0% | 10.9% | ||
| Q4 24 | 17.6% | 16.3% | ||
| Q3 24 | 15.8% | 14.3% | ||
| Q2 24 | 13.6% | 12.4% |
| Q1 26 | 17.2% | — | ||
| Q4 25 | 14.5% | 12.7% | ||
| Q3 25 | 16.7% | 6.7% | ||
| Q2 25 | 14.8% | 7.5% | ||
| Q1 25 | 13.1% | 6.4% | ||
| Q4 24 | 12.4% | 13.0% | ||
| Q3 24 | 11.8% | 13.8% | ||
| Q2 24 | 11.7% | 8.0% |
| Q1 26 | $2.77 | — | ||
| Q4 25 | $2.09 | $0.86 | ||
| Q3 25 | $2.43 | $0.40 | ||
| Q2 25 | $2.21 | $0.46 | ||
| Q1 25 | $1.88 | $0.35 | ||
| Q4 24 | $1.66 | $0.77 | ||
| Q3 24 | $1.67 | $0.77 | ||
| Q2 24 | $1.85 | $0.45 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $294.8M | $919.9M |
| 総負債低いほど良い | $690.4M | — |
| 株主資本純資産 | $2.1B | $7.3B |
| 総資産 | $3.7B | $12.2B |
| 負債/資本比率低いほどレバレッジが低い | 0.33× | — |
8四半期トレンド — 暦四半期で整列
| Q1 26 | $294.8M | — | ||
| Q4 25 | $231.9M | $919.9M | ||
| Q3 25 | $208.0M | $931.4M | ||
| Q2 25 | $315.5M | $991.8M | ||
| Q1 25 | $151.5M | $1.1B | ||
| Q4 24 | $162.1M | $1.2B | ||
| Q3 24 | $150.2M | $1.2B | ||
| Q2 24 | $199.1M | $2.0B |
| Q1 26 | $690.4M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $2.1B | — | ||
| Q4 25 | $2.0B | $7.3B | ||
| Q3 25 | $1.9B | $7.4B | ||
| Q2 25 | $1.9B | $7.6B | ||
| Q1 25 | $1.8B | $7.6B | ||
| Q4 24 | $1.7B | $7.7B | ||
| Q3 24 | $1.7B | $7.9B | ||
| Q2 24 | $1.6B | $7.9B |
| Q1 26 | $3.7B | — | ||
| Q4 25 | $3.5B | $12.2B | ||
| Q3 25 | $3.4B | $12.1B | ||
| Q2 25 | $3.5B | $12.4B | ||
| Q1 25 | $3.4B | $12.4B | ||
| Q4 24 | $3.3B | $12.4B | ||
| Q3 24 | $3.3B | $12.8B | ||
| Q2 24 | $3.3B | $13.4B |
| Q1 26 | 0.33× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | — | $182.0M |
| フリーキャッシュフロー営業CF - 設備投資 | $124.8M | $161.8M |
| FCFマージンFCF / 売上 | 15.4% | 21.0% |
| 設備投資強度設備投資 / 売上 | — | 2.6% |
| キャッシュ転換率営業CF / 純利益 | — | 1.85× |
| 直近12ヶ月FCF直近4四半期 | $407.5M | $509.4M |
8四半期トレンド — 暦四半期で整列
| Q1 26 | — | — | ||
| Q4 25 | $132.2M | $182.0M | ||
| Q3 25 | $39.2M | $138.5M | ||
| Q2 25 | $258.1M | $134.3M | ||
| Q1 25 | $74.2M | $128.2M | ||
| Q4 24 | $67.9M | $174.2M | ||
| Q3 24 | $40.2M | $147.9M | ||
| Q2 24 | $169.5M | $158.6M |
| Q1 26 | $124.8M | — | ||
| Q4 25 | $85.9M | $161.8M | ||
| Q3 25 | $-3.4M | $120.0M | ||
| Q2 25 | $200.2M | $115.5M | ||
| Q1 25 | $34.0M | $112.2M | ||
| Q4 24 | $38.6M | $149.8M | ||
| Q3 24 | $13.3M | $125.6M | ||
| Q2 24 | $141.8M | $136.6M |
| Q1 26 | 15.4% | — | ||
| Q4 25 | 11.8% | 21.0% | ||
| Q3 25 | -0.5% | 17.2% | ||
| Q2 25 | 26.5% | 16.0% | ||
| Q1 25 | 4.7% | 16.9% | ||
| Q4 24 | 5.7% | 20.5% | ||
| Q3 24 | 1.9% | 18.4% | ||
| Q2 24 | 17.8% | 19.7% |
| Q1 26 | — | — | ||
| Q4 25 | 6.4% | 2.6% | ||
| Q3 25 | 5.8% | 2.6% | ||
| Q2 25 | 7.7% | 2.6% | ||
| Q1 25 | 5.5% | 2.4% | ||
| Q4 24 | 4.3% | 3.4% | ||
| Q3 24 | 3.7% | 3.3% | ||
| Q2 24 | 3.5% | 3.2% |
| Q1 26 | — | — | ||
| Q4 25 | 1.26× | 1.85× | ||
| Q3 25 | 0.32× | 2.97× | ||
| Q2 25 | 2.31× | 2.49× | ||
| Q1 25 | 0.78× | 3.03× | ||
| Q4 24 | 0.81× | 1.84× | ||
| Q3 24 | 0.47× | 1.57× | ||
| Q2 24 | 1.81× | 2.87× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
CRS
| Aerospace and Defense | $435.6M | 54% |
| Surcharge revenue | $155.9M | 19% |
| Industrial and Consumer | $78.1M | 10% |
| Medical | $51.7M | 6% |
| Energy | $50.5M | 6% |
| Distribution | $20.4M | 3% |
| Transportation | $19.3M | 2% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
